Investigating the role of the complement pathway in lung diseases
Complement Pathway Activation in Idiopathic Pulmonary Fibrosis and other Progressive Fibrosing Interstitial Lung Diseases
This study is looking at how certain proteins in your body might help us understand the progression of idiopathic pulmonary fibrosis and similar lung diseases, so we can find better treatments tailored just for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11011341 on NIH RePORTER |
What this research studies
This research focuses on idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases (PF-ILDs), which lead to severe lung function decline. The study aims to understand how the complement pathway, a part of the immune system, may serve as a biomarker for disease progression and acute respiratory events. By analyzing specific proteins and genetic variations in patients, the research seeks to identify those who may benefit from targeted therapies. The ultimate goal is to develop novel treatments that improve patient outcomes and personalize care based on biomarker findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis or other progressive fibrosing interstitial lung diseases.
Not a fit: Patients with non-progressive lung diseases or those not diagnosed with PF-ILD may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options and improved management strategies for patients with PF-ILD.
How similar studies have performed: Previous research has shown promise in using biomarkers for disease progression in similar lung conditions, indicating potential for success in this approach.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Swaminathan, Aparna Chandra — Duke University
- Study coordinator: Swaminathan, Aparna Chandra
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.